Voyager Therapeutics, Inc. (VYGR)
$2.15-5.29%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $130M
- Beta
- 1.28
- P/E (TTM)
- -1.19
- Short % float
- 7.88%
- Days to cover
- 6.4
- SI change
- +8.7%
- 1W
- -12.60%
- 1M
- -32.60%
- vs SPY 1W
- -12.46%
- vs SPY 1M
- -35.11%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 5
- GROWTH
- 41
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-34.8%
REV YoY-
ROE-57.9%
EPS YoY-
ROA-54.5%
GROSS100
OP-340
NET-313
[VALUATION]
P/E TTM-1.19
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.84
P/FCF-
EV/EBITDA-1.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E21.10
ALTMAN Z-
CURR RATIO7.51
ND/EBITDA-
BETA1.28
Company news
FAQ
- What is LOPJLB’s current signal on VYGR?
- LOPJLB’s latest quantitative signal on Voyager Therapeutics, Inc. (VYGR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VYGR in?
- Voyager Therapeutics, Inc. (VYGR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Voyager Therapeutics, Inc. (VYGR) do?
- Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophi…